<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Cancer</journal-id><journal-id journal-id-type="iso-abbrev">BMC Cancer</journal-id><journal-title-group><journal-title>BMC Cancer</journal-title></journal-title-group><issn pub-type="epub">1471-2407</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5020520</article-id><article-id pub-id-type="publisher-id">2764</article-id><article-id pub-id-type="doi">10.1186/s12885-016-2764-5</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Does native <italic>Trypanosoma cruzi</italic> calreticulin mediate growth inhibition of a mammary tumor during infection?</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Abello-C&#x000e1;ceres</surname><given-names>Paula</given-names></name><address><email>paula.abello.c@gmail.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Pizarro-Bauerle</surname><given-names>Javier</given-names></name><address><email>jpizarrob@ug.uchile.cl</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Rosas</surname><given-names>Carlos</given-names></name><address><email>crosasc@med.uchile.cl</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Maldonado</surname><given-names>Ismael</given-names></name><address><email>ismael_amf@yahoo.es</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Aguilar-Guzm&#x000e1;n</surname><given-names>Lorena</given-names></name><address><email>ena_vet@yahoo.com</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Gonz&#x000e1;lez</surname><given-names>Carlos</given-names></name><address><email>cmgonza@gmail.com</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Ram&#x000ed;rez</surname><given-names>Galia</given-names></name><address><email>galiaram@uchile.cl</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Ferreira</surname><given-names>Jorge</given-names></name><address><email>jferreir@med.uchile.cl</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Ferreira</surname><given-names>Arturo</given-names></name><address><phone>+56 2 9786723</phone><email>aferreira_uchile@yahoo.com</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><aff id="Aff1"><label>1</label>Institute of Biomedical Sciences (ICBM), Faculty of Medicine, University of Chile, Avenida Independencia 1027, Independencia, Santiago, Chile </aff><aff id="Aff2"><label>2</label>Faculty of Veterinary Medicine and Livestock Sciences, University of Chile, Avenida Santa Rosa 11735, La Pintana, Santiago, Chile </aff><aff id="Aff3"><label>3</label>Faculty of Veterinary Medicine, Andr&#x000e9;s Bello University, Avenida Rep&#x000fa;blica 440, Santiago Centro, Santiago, Chile </aff><aff id="Aff4"><label>4</label>University of Chile, Avenida Independencia 1027, Santiago, Chile </aff></contrib-group><pub-date pub-type="epub"><day>13</day><month>9</month><year>2016</year></pub-date><pub-date pub-type="pmc-release"><day>13</day><month>9</month><year>2016</year></pub-date><pub-date pub-type="collection"><year>2016</year></pub-date><volume>16</volume><issue>1</issue><elocation-id>731</elocation-id><history><date date-type="received"><day>9</day><month>5</month><year>2016</year></date><date date-type="accepted"><day>27</day><month>8</month><year>2016</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s). 2016</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p>For several decades now an antagonism between <italic>Trypanosoma cruzi</italic> infection and tumor development has been detected. The molecular basis of this phenomenon remained basically unknown until our proposal that <italic>T. cruzi</italic> Calreticulin (TcCRT), an endoplasmic reticulum-resident chaperone, translocated-externalized by the parasite, may mediate at least an important part of this effect. Thus, recombinant TcCRT (rTcCRT) has important in vivo antiangiogenic and antitumor activities. However, the relevant question whether the in vivo antitumor effect of <italic>T. cruzi</italic> infection is indeed mediated by the native chaperone (nTcCRT), remains open. Herein, by using specific modified anti-rTcCRT antibodies (Abs), we have neutralized the antitumor activity of <italic>T. cruzi</italic> infection and extracts thereof, thus identifying nTcCRT as a valid mediator of this effect.</p></sec><sec><title>Methods</title><p>Polyclonal anti-rTcCRT F(ab&#x02019;)<sub>2</sub> Ab fragments were used to reverse the capacity of rTcCRT to inhibit EAhy926 endothelial cell (EC) proliferation, as detected by BrdU uptake. Using these F(ab&#x02019;)<sub>2</sub> fragments, we also challenged the capacity of nTcCRT, during <italic>T. cruzi</italic> infection, to inhibit the growth of an aggressive mammary adenocarcinoma cell line (TA3-MTXR) in mice. Moreover, we determined the capacity of anti-rTcCRT Abs to reverse the antitumor effect of an epimastigote extract (EE). Finally, the effects of these treatments on tumor histology were evaluated.</p></sec><sec><title>Results</title><p>The rTcCRT capacity to inhibit ECs proliferation was reversed by anti-rTcCRT F(ab&#x02019;)<sub>2</sub> Ab fragments, thus defining them as valid probes to interfere in vivo with this important TcCRT function. Consequently, during infection, these Ab fragments also reversed the in vivo experimental mammary tumor growth. Moreover, anti-rTcCRT Abs also neutralized the antitumor effect of an EE, again identifying the chaperone protein as an important mediator of this anti mammary tumor effect. Finally, as determined by conventional histological parameters, in infected animals and in those treated with EE, less invasive tumors were observed while, as expected, treatment with F(ab&#x02019;)<sub>2</sub> Ab fragments increased malignancy.</p></sec><sec><title>Conclusion</title><p>We have identified translocated/externalized nTcCRT as responsible for at least an important part of the anti mammary tumor effect of the chaperone observed during experimental infections with <italic>T. cruzi</italic>.</p></sec><sec><title>Electronic supplementary material</title><p>The online version of this article (doi:10.1186/s12885-016-2764-5) contains supplementary material, which is available to authorized users.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Mammary tumor</kwd><kwd><italic>Trypanosoma cruzi</italic></kwd><kwd>Calreticulin</kwd><kwd>Angiogenesis</kwd></kwd-group><funding-group><award-group><funding-source><institution>Regular Fondecyt Project (CONICYT-Chile)</institution></funding-source><award-id>1130099</award-id><principal-award-recipient><name><surname>Ferreira</surname><given-names>Arturo</given-names></name></principal-award-recipient></award-group><award-group><funding-source><institution>Bicentennial Associative Research (CONICYT-Chile)</institution></funding-source><award-id>ACT-112</award-id><principal-award-recipient><name><surname>Ferreira</surname><given-names>Arturo</given-names></name></principal-award-recipient></award-group><award-group><funding-source><institution>CONICYT Doctoral Fellowship</institution></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2016</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p>In this report, we identify a protein from the <italic>Trypanosoma cruzi</italic> (the protozoan agent of Chagas disease) endoplasmic reticulum (ER), as responsible for, at least an important part of the antitumor effect of this infection.</p><p>Chagas&#x02019; disease (American Trypanosomiasis) is mainly spread by <italic>Triatominae</italic> insects. Originally confined to America, the disease has now gone global [<xref ref-type="bibr" rid="CR1">1</xref>].</p><p>Only 30&#x000a0;% of <italic>T. cruzi</italic> infected people presents variable symptoms, years or decades after infection [<xref ref-type="bibr" rid="CR1">1</xref>], thus indicating that the protozoan components, as occurs in many parasitisms, are relatively well tolerated during the infection.</p><p>Interestingly, several reports indicate that in patients with Chagas&#x02019; disease cancer is an extremely rare event, in particular breast adenocarcinomas. Thus, about 80&#x000a0;years ago, Roskin, Ekzempliarskaia and Klyuyeva, researchers from the former Soviet Union, postulated an experimental anticancer toxic activity derived from this infection. When they inoculated <italic>T. cruzi</italic> extracts, directly in a peritumoral area, in different tumors, both in experimental animals and in humans, similar results to those obtained with the infection were generated. Moreover, the parasite capacity to infect preferentially tumor cells, as compared to normal host cells, was also described (reviewed in [<xref ref-type="bibr" rid="CR2">2</xref>]). Although, in general, these data suggest an antagonism between <italic>T. cruzi</italic> infection and tumor growth [<xref ref-type="bibr" rid="CR3">3</xref>], research progress in these areas was seriously hampered by the intense international political problems of those years (i.e. the Cold War) [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>]. Although several publications on these issues have appeared during the last decade [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR6">6</xref>&#x02013;<xref ref-type="bibr" rid="CR8">8</xref>], the molecular basis of this phenomenon has remained elusive.</p><p>Our laboratory interest in understanding molecular terms ruling the host/parasite interplay has led us to the identification, sequencing, cloning, expression and characterization of a 45&#x000a0;kDa protein, <italic>T. cruzi</italic> Calreticulin (TcCRT), an ER-resident chaperone [<xref ref-type="bibr" rid="CR9">9</xref>&#x02013;<xref ref-type="bibr" rid="CR14">14</xref>]. We have described three domains in recombinant TcCRT (rTcCRT): N-terminal (N-TcCRT) (aa 120&#x02013;180), with antiangiogenic activity [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR15">15</xref>]; central-S (aa 159&#x02013;281), that binds and inhibits human C1, the first component of the complement system, [<xref ref-type="bibr" rid="CR16">16</xref>] and, P (aa173&#x02013;286), mainly involved in calcium binding [<xref ref-type="bibr" rid="CR16">16</xref>].</p><p>Most important, during infection TcCRT is exteriorized from the ER to the area of flagellum emergence [<xref ref-type="bibr" rid="CR16">16</xref>]. We have shown that rTcCRT inhibits angiogenesis (in vitro<italic>, ex vivo, in ovum</italic> and in vivo) in three vertebrate species (<italic>Rattus rattus, Gallus gallus</italic> and <italic>Homo sapiens sapiens</italic>) [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR17">17</xref>], and that it interferes with morphogenesis, migration and proliferation of endothelial cells (ECs) [<xref ref-type="bibr" rid="CR9">9</xref>]. When ECs were incubated with rTcCRT, we observed that the protein was internalized. This internalization is inhibited by fluid-phase Fucoidan [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>], a sulfated polysaccharide and ligand for Scavenger Receptors (SR) [<xref ref-type="bibr" rid="CR18">18</xref>].</p><p>The parasite cycle in the mammal host implies that, from the original infection site caused by the hematophagous arthropod vector, <italic>T. cruzi</italic> must access the circulation in order to reach its target tissues (mainly heart, esophagus, colon and aorta) [<xref ref-type="bibr" rid="CR1">1</xref>]. Once in the circulation, the parasite must swiftly contact the ECs apical membrane surface. In this key step and since ECs display receptors (cC1qR) for complement component C1 [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR20">20</xref>], a synapse will be formed by parasite TcCRT, host C1 and EC (host) CRT (cC1qR) (reviewed in [<xref ref-type="bibr" rid="CR2">2</xref>]). Alternatively or concomitantly, <italic>T. cruzi</italic> ability to contact and infect ECs may involve direct interaction of TcCRT with a constitutive SR present on ECs [<xref ref-type="bibr" rid="CR21">21</xref>&#x02013;<xref ref-type="bibr" rid="CR23">23</xref>].</p><p>rTcCRT, inoculated in a peritumoral area, reduced the growth of an aggressive, multiresistant mammary adenocarcinoma (TA3-MTXR) in mice [<xref ref-type="bibr" rid="CR9">9</xref>]. The rTcCRT antiangiogenic activity and antitumor effects were more efficient than those mediated by human CRT (rHuCRT), when compared at equimolar concentrations [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR17">17</xref>].</p><p>However, these facts do not necessarily mean that native parasite CRT (nTcCRT), indeed mediates the infection antineoplastic effect. This important question is justified by the following rationale: i). The possibility exists that one or several, still unidentified parasite molecules, could largely mediate the important antitumor effects observed during <italic>T. cruzi</italic> infection (or after injection of parasite lysates); ii). Given the cloning procedures, recombinant (rTcCRT) used in vivo in the previously reported experiments [<xref ref-type="bibr" rid="CR14">14</xref>], is structurally different from the native version operating during infection (e.g.: addition of a polyhistidine tail, lack of glycosylations, marginal LPS contamination, protein degradation, among other possibilities); iii). The experimental conditions of the reported in vivo treatment of tumor-bearing animals with rTcCRT [<xref ref-type="bibr" rid="CR9">9</xref>] (i.e. the protein is injected several times in peritumor sites) are radically different from those mediated by an experimental or natural infection with the parasite and, iv). CRTs from different species were traditionally located in the ERs, and all of them carry a carboxiterminal ER-retention signal (KDEL, in TcCRT) [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR24">24</xref>]. Although nTcCRT is translocated to the parasite area of flagellum emergence [<xref ref-type="bibr" rid="CR15">15</xref>], we have no firm vidence that the chaperone can diffuse to the surrounding fluid phase. Antibody (Ab) -targeted neutralization of its antitumor effects during infection is thus informative with regard to this important function.</p><p>Herein, we propose that, during <italic>T. cruzi</italic> infection, the responsible antitumor molecule is nTcCRT expressed by the parasite. We have been able to revert the antitumor effect of the infection by targeting nTcCRT with specific Abs, among the multitude of parasite molecules present in the infecting parasite (or extracts thereof).</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Reagents, recombinant proteins and Abs</title><p>rTcCRT and its N-TcCRT domain, rabbit whole anti-rTcCRT Abs, their preimmune counterparts, as well as their F(ab&#x02019;)<sub>2</sub> fragments, were all generated, in our laboratory, by immunizing rabbits with the pure recombinant molecule, by standard procedures [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR25">25</xref>]. All these Abs were monospecific since, in immunowestern assays they recognized only nTcCRT in whole <italic>T. cruzi</italic> extracts. The rationale for choosing whole anti-rTcCRT Abs or their F(ab&#x02019;)<sub>2</sub> fragments, in the experiments described below, is examined in the Discussion section.</p></sec><sec id="Sec4"><title>Capacity of F(ab&#x02019;)<sub>2</sub> anti-rTcCRT Ab fragments to prevent the chaperone binding to human ECs</title><p>The experimental design aimed at studying the capacity of anti-rTcCRT F(ab&#x02019;)<sub>2</sub> Ab fragments to neutralize the interaction of the parasite chaperone with human ECs. Two types of Fucoidan were used as positive controls [<xref ref-type="bibr" rid="CR9">9</xref>]. First, 2x10<sup>5</sup> ECs (EAhy926) [<xref ref-type="bibr" rid="CR26">26</xref>] (donated by Dr. Gareth Owen, Pontifical Catholic University of Chile), were seeded in IMDM (Iscove&#x02019;s Modified Dulbecco&#x02019;s Medium, Invitrogen, USA). The medium was supplemented with 10&#x000a0;%&#x000a0;v/v heat-inactivated fetal bovine serum (FBS, Invitrogen, USA), 1&#x000a0;% penicillin/streptomycin (Sigma, USA), 1&#x000a0;% glutamine (Invitrogen, USA) and sodium bicarbonate 0.3&#x000a0;M (MERCK, Germany). The cells were collected at 80&#x000a0;% confluence and expanded. rTcCRT was coupled to FITC (F-rTcCRT) according to manufacturer&#x02019;s instructions (FluoReporter FITC Protein Labeling Kit, Molecular Probes, USA).</p><p>Later, in eight in vitro experimental groups, 3&#x000d7;10<sup>5</sup> EAhy926 cells were incubated in 96-well flat bottom plates, for 6&#x000a0;h, at 37&#x000a0;&#x000b0;C, adding: i.) F-rTcCRT (1&#x000a0;&#x003bc;M); ii.) F-rTcCRT with anti-rTcCRT F(ab&#x02019;)<sub>2</sub> fragments (120&#x000a0;&#x003bc;g); iii.) F-rTcCRT and preimmune Ab fragments; iv.) F-rTcCRT, with Fucoidan 1 (Mw&#x02009;=&#x02009;20&#x02013;200&#x000a0;kDa) (Sigma-Aldrich, USA) (100&#x000a0;&#x003bc;g); v.) F-rTcCRT, with Fucoidan 2 (Mw&#x02009;=&#x02009;58.6&#x000a0;kDa) (Sigma-Aldrich, USA) (100&#x000a0;&#x003bc;g); vi.) N-rTcCRT; vii.) N-rTcCRT with Fucoidan 1 and, viii.) N-rTcCRT with Fucoidan 2.</p><p>After 6&#x000a0;h incubations, the cells were analyzed by flow cytometry (BD FACSAria III) (20.000 events) using the software FCS Express 5.</p></sec><sec id="Sec5"><title>Capacity of F(ab&#x02019;)<sub>2</sub> anti-rTcCRT Ab fragments to revert the rTcCRT-dependent inhibition of EC proliferation</title><p>The EAhy926 cells origin, culture and harvesting conditions were described above. Reversion of the anti-proliferative rTcCRT effect on ECs was detected by BrdU uptake (BrdU Cell Proliferation Assay Kit, Millipore&#x000a9; cat. 2750). Briefly, 3&#x000d7;10<sup>4</sup> ECs were incubated in 96-well flat bottom plates (Nunc, UK), for 24, 48 and 72&#x000a0;h. ECs were the incubated with rTcCRT (1&#x000a0;&#x003bc;M) and/or 80&#x000a0;&#x003bc;g in 200&#x000a0;&#x003bc;l of F(ab&#x02019;)<sub>2</sub> fragments (anti-rTcCRT or preimmune controls). Results were expressed as percentage compared to the control group (100&#x000a0;% proliferation).</p></sec><sec id="Sec6"><title>Tumor, induction and evaluation</title><p>The methotrexate (MTX)-resistant (MTXR) cell line (TA3-MTXR) [<xref ref-type="bibr" rid="CR27">27</xref>], was originally isolated from the TA3 mammary adenocarcinoma, grown as ascites by weekly i.p. injections of 10<sup>6</sup> cells into histocompatible mice [<xref ref-type="bibr" rid="CR28">28</xref>]. The TA3-MTXR mammary tumor cell line was generated by weekly consecutive selection in the presence of MTX [<xref ref-type="bibr" rid="CR28">28</xref>]. The tumor cells TA3-MTXR used herein were extracted from mouse ascites, diluted in physiological saline solution and centrifuged at 423G for 5&#x000a0;min at room temperature. The supernatant was discarded and the pellet was suspended in physiological saline, and counted in a Neubauer chamber. Over 95&#x000a0;% tumor cell viability was routinely obtained.</p><p>In all experiments, mice were inoculated s.c. on the supra scapular region, with 5&#x000d7;10<sup>5</sup> TA3-MTXR, freshly obtained mammary tumor cells, contained in 100&#x000a0;&#x003bc;l.</p><p>Evaluation of tumor growth was blindly monitored, for 30&#x000a0;days [<xref ref-type="bibr" rid="CR11">11</xref>] and, in compliance with bioethical regulations, until they reached a maximum of 3.000&#x000a0;mm<sup>3</sup>, when the animals were euthanized. In each test, the minimum number of animals per experimental group was eight, unless otherwise defined, a calculation based on mean values and their standard deviations, obtained in previous experiments [<xref ref-type="bibr" rid="CR29">29</xref>].</p></sec><sec id="Sec7"><title>Immune mediated specific reversion of the antitumor effects of rTcCRT</title><p>Five experimental groups were designed. All of them were inoculated with the TA3-MTXR tumor cells. In addition the animals were treated as follows: Group I: PBS, as positive control (s.c.); Group 2: rTcCRT (50&#x000a0;&#x003bc;g, s.c.); Group 3: In order to reverse the rTcCRT antitumor capacity, this group was inoculated with whole anti-rTcCRT Abs (500&#x000a0;&#x003bc;g); Group 4: As a negative control these mice received preimmune Abs and, Group 5: N-rTcCRT.</p><p>All inoculations were performed every other day on a peritumor area.</p></sec><sec id="Sec8"><title>Immune mediated specific reversion of the antitumor effects of a trypomastigote infection</title><p>Four experimental groups were designed. All of them were inoculated with the TA3-MTXR tumor cells. In addition the animals were treated as follows: Group I: PBS, as positive control (i.v); Group 2: Mice were infected i.p. with 10<sup>3</sup> trypomastigotes (infective form) of the Tulahu&#x000e9;n strain; Group 3: In order to reverse the antitumor capacity of the infection, mice were also inoculated, in the lateral tail vein, with F(ab&#x02019;)<sub>2</sub> anti-rTcCRT Abs (200&#x000a0;&#x003bc;g in 100&#x000a0;&#x003bc;l) and, Group 4: As a negative control, these mice received preimmune F(ab&#x02019;)<sub>2</sub> Abs. All groups were inoculated with TA3-MTXR tumor cells on day 8, corresponding to the parasitemia peak.</p></sec><sec id="Sec9"><title>Immune mediated specific reversion of the antitumor effects of an epimastigote extract</title><p>Epimastigotes are <italic>T. cruzi</italic> non-infective forms, obtained from axenic cultures [<xref ref-type="bibr" rid="CR30">30</xref>]. They express nTcCRT, although their capacity to translocate the chaperone to the area of flagellum emergence is absent or marginal [<xref ref-type="bibr" rid="CR31">31</xref>]. We first asked whether an epimastigote extract (EE) reproduces the in vivo antitumor effect of infective trypomastigotes and if this effect is inhibited by whole anti-rTcCRT Abs, based on the rationale described at the beginning of this section. The Tulahu&#x000e9;n clone (donated by Dr. Juan Diego Maya, ICBM, Faculty of Medicine, University of Chile), was grown at 28&#x000a0;&#x000b0;C in modified Diamond&#x02019;s medium [<xref ref-type="bibr" rid="CR30">30</xref>] and 2&#x000d7;10<sup>6</sup> parasites were used to prepare the EE, by standard procedures [<xref ref-type="bibr" rid="CR32">32</xref>].</p><p>Four experimental groups were designed. All of them were inoculated with the TA3-MTXR tumor cells. In addition, the animals were treated as follows: Group I: PBS, as positive control (s.c.); Group 2: EE, s.c.; Group 3: In order to reverse the antitumor capacity of EE, this group was inoculated with whole anti-rTcCRT Abs (200&#x000a0;&#x003bc;g); Group 4: As a negative control these mice received preimmune Abs.</p><p>All inoculations were performed every other day on a peritumor area.</p></sec><sec id="Sec10"><title>Immune mediated specific reversion of the antitumor effects of trypomastigote infection or epimastigote extract, as assessed by histopathology</title><p>Tumors were extracted and fixed with 10&#x000a0;% formalin for 48&#x000a0;h, dehydrated and clarified [<xref ref-type="bibr" rid="CR11">11</xref>]. The sections were embedded on paraffin (Paraplast Plus&#x000ae;, Sigma-Aldrich, USA) and 4&#x000a0;&#x003bc;m thick slices were stained with Hematoxylin-Eosin, and mounted with Entell&#x000e1;n&#x000ae;. A description of the main lesions observed in the tumor samples was performed on 10 fields of 40 and 400&#x000d7; zoom, in an Olympus FS100 microscope.</p></sec><sec id="Sec11"><title>Statement of bioethical approval</title><p>Our Institutional Bioethics Committee approved the experimental protocols using animals. Eight to 12-week-old female A/J mice were maintained under internationally accepted guidelines in our Animal Facility (Faculty of Medicine, University of Chile).</p></sec><sec id="Sec12"><title>Statistical analyses</title><p>When pertinent, experimental data were statistically validated by One or Two-Way ANOVA and <italic>post-hoc</italic> Bonferroni&#x02019;s Multiple Comparison and also by one-tailed Wilcoxon Signed-Rank, using the software GraphPad Prism 5.</p></sec></sec><sec id="Sec13"><title>Results</title><sec id="Sec14"><title>rTcCRT and its N-domain interactions with ECs can be interfered with Abs or Fucoidan</title><p>rTcCRT contact with ECs is a prerequisite for the inhibition of cell proliferation and migration, two crucial events in angiogenesis [<xref ref-type="bibr" rid="CR9">9</xref>]. Most likely rTcCRT interacts with SRs present on human ECs [<xref ref-type="bibr" rid="CR21">21</xref>&#x02013;<xref ref-type="bibr" rid="CR23">23</xref>]. In such a case, Abs against rTcCRT or, fluid-phase Fucoidans (specific SR ligands), should interfere with the EC/rTcCRT interaction in vitro. Figure&#x000a0;<xref rid="Fig1" ref-type="fig">1a, c</xref> show typical flow cytometry analyses, while Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1b, d</xref>, summarize their respective statistical validations. Figure&#x000a0;<xref rid="Fig1" ref-type="fig">1a</xref> shows that anti-rTcCRT F(ab&#x02019;)<sub>2</sub> fragments inhibit the F-rTcCRT/EC interaction (<italic>p</italic>&#x02009;&#x0003c;&#x02009;10<sup>&#x02212;4</sup>). Figure&#x000a0;<xref rid="Fig1" ref-type="fig">1c</xref> shows that two types of Fucoidans do interfere with this interaction (<italic>p</italic>&#x02009;&#x0003c;&#x02009;10<sup>&#x02212;4</sup>), as valid positive controls. The F-N-rTcCRT interaction with ECs was similarly inhibited by Fucoidan 1 and Fucoidan 2 (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05, in both cases). Moreover, and as expected, F-rTcCRT and F-N-rTcCRT interactions with ECs were similar (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1e</xref>-<xref rid="Fig1" ref-type="fig">f</xref>).<fig id="Fig1"><label>Fig. 1</label><caption><p>The interaction of rTcCRT and its N-domain with ECs can be intervened by Abs or Fucoidan. Using flow cytometry, human ECs (EAhy926) were incubated with F-rTcCRT in the presence of: <bold>a</bold> Anti-rTcCRT F(ab&#x02019;)<sub>2</sub> fragments or their preimmune counterparts; <bold>c</bold> Fucoidans 1 or 2. EAhy926 cells were also incubated with: <bold>e</bold> F-N-rTcCRT or alternatively with F-N-rTcCRT and Fucoidans 1 or 2. Statistical validation: <bold>b d</bold> and <bold>f</bold> (One-Way ANOVA and a <italic>post-hoc</italic> Bonferroni&#x02019;s multiple comparison test</p></caption><graphic xlink:href="12885_2016_2764_Fig1_HTML" id="MO1"/></fig></p></sec><sec id="Sec15"><title>Whole anti-rTcCRT Abs and their F(ab&#x02019;)<sub>2</sub> fragments abrogate the rTcCRT-dependent inhibition of EC proliferation</title><p>Since, as shown above, rTcCRT interaction with ECs is reversed by anti-rTcCRT Abs (and also by fluid-phase Fucoidans), we asked whether these Abs also abrogate the chaperone capacity to inhibit EC proliferation. We determined that, while the F(ab&#x02019;)<sub>2</sub> Ab fragments inhibited ECs proliferation at 24, 48 and 72&#x000a0;h of incubation (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001, in all cases), the inhibitory capacity of their whole counterparts was detectable only at 48 and 72&#x000a0;h (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05 and <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01, respectively) (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). Since these experiments were conducted in the absence of C1, it is then possible that these Abs interfere with the rTcCRT capacity to interact with SRs present on ECs.<fig id="Fig2"><label>Fig. 2</label><caption><p>Whole anti-rTcCRT Abs and their F(ab&#x02019;)<sub>2</sub> fragments revert the rTcCRT-dependent inhibition of EC proliferation. Human ECs (EAhy926) were incubated with rTcCRT, in addition to whole anti-rTcCRT Abs, their respective F(ab&#x02019;)<sub>2</sub> fragments or the preimmune counterpart of each Ab type. Proliferation was analyzed by incorporation of BrdU and expressed as percentage, where 100&#x000a0;% corresponds to cells incubated with medium alone (Two-Way ANOVA and a <italic>post-hoc</italic> Bonferroni&#x02019;s multiple comparison test)</p></caption><graphic xlink:href="12885_2016_2764_Fig2_HTML" id="MO2"/></fig></p></sec><sec id="Sec16"><title>Immune mediated specific abrogation of the anti mammary tumor effects of rTcCRT</title><p>If the in vivo antitumor effect of <italic>T. cruzi</italic> infection is indeed mediated by translocated/exteriorized nTcCRT [<xref ref-type="bibr" rid="CR16">16</xref>], this effect should be reversed by anti-rTcCRT Abs. We first validated these Abs with regard to their capacity to revert the antitumor effect of rTcCRT, already reported by our laboratory [[<xref ref-type="bibr" rid="CR9">9</xref>&#x02013;<xref ref-type="bibr" rid="CR12">12</xref>]. Indeed, this property was abrogated by these Abs, and tumor growth reached levels similar to those of the negative control group (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3a</xref>). (Noteworthy, this experiment also confirms the potent antitumor effect reported for rTcCRT [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR11">11</xref>], used here as a positive control). Additionally and as expected, the N-rTcCRT domain maintains the antitumor effect of its whole counterpart, as shown in Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3b</xref>.<fig id="Fig3"><label>Fig. 3</label><caption><p>The anti mammary tumor effect of rTcCRT is reversed by whole anti-rTcCRT Abs and the N-rTcCRT domain retains the effect of the full recombinant protein. A/J mice were inoculated s.c., in a supra escapular area, with mammary adenocarcinoma cells (TA3-MTXR, control group) and challenged as indicated in the Figures and detailed in the Materials and Methods section. <bold>a</bold> Reversion of the rTcCRT antitumor effect; <bold>b</bold> N-rTcCRT antitumor effect. Recombinant proteins and Abs were delivered every other day. (One-tailed Wilcoxon signed-rank test)</p></caption><graphic xlink:href="12885_2016_2764_Fig3_HTML" id="MO3"/></fig></p></sec><sec id="Sec17"><title>Specific anti-rTcCRT Abs abrogate the mammary antitumor effects of <italic>T. cruzi</italic> infection</title><p>The rationale for choosing F(ab&#x02019;)<sub>2</sub> Ab fragments to revert the antitumor effects of a trypomastigote infection is based mainly on the fact that <italic>T. cruzi</italic> translocates its TcCRT to the area of parasite flagellum emergence, where it binds complement C1 [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR33">33</xref>]. The Fc-dependent IgG capacity of whole anti-rTcCRT Abs to recruit additional C1 is absent in F(ab&#x02019;)<sub>2</sub> fragments; thus these fragments block infectivity [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR33">33</xref>] and possibly the parasite antitumor properties. We therefore propose that this <italic>T. cruzi</italic> translocated nTcCRT contacts ECs, thus exerting an antiangiogenic effect, followed by inhibition of tumor growth. In fact, those animals inoculated with anti-rTcCRT F(ab&#x02019;)<sub>2</sub> fragments showed an inhibition of the antitumor effect associated with this infection (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>). We have thus established a causal relationship between parasite nTcCRT and the antitumor effect of this infection.<fig id="Fig4"><label>Fig. 4</label><caption><p>The anti mammary tumor effects of <italic>T. cruzi</italic> infection is reversed by specific anti-rTcCRT F(ab&#x02019;)<sub>2</sub> fragments. A/J mice were inoculated s.c. in a supra escapular area with mammary adenocarcinoma cells (TA3-MTXR, control group) and challenged as indicated in the Figure and detailed in the Materials and Methods section. In all cases the infection with <italic>T. cruzi</italic> was performed 8&#x000a0;days before the inoculation of tumor cells, and the delivery of Abs was performed every other day. (One-tailed Wilcoxon signed-rank test)</p></caption><graphic xlink:href="12885_2016_2764_Fig4_HTML" id="MO4"/></fig></p></sec><sec id="Sec18"><title>An epimastigote extract displays an anti mammary tumor effect that can be also reversed by specific anti-rTcCRT Abs</title><p>The original experiments of Roskin and Klyuyeva included the direct inoculation, at the tumor site, of a lysate of blood trypomastigotes, with antitumor consequences (reviewed in [<xref ref-type="bibr" rid="CR2">2</xref>]). We used EE (prepared with non-infective parasites) instead, that displayed a single band, compatible with nTcCRT, when detected with specific polyclonal and monoclonal Abs, in conventional immunowesternblotting [<xref ref-type="bibr" rid="CR34">34</xref>]. We inoculated the animals with whole anti-rTcCRT Abs, aiming at neutralizing the EE parasite protein capacity to inhibit tumor growth.</p><p>As predicted, in the EE-treated group, smaller tumor sizes and even full tumor regression was observed. When anti-rTcCRT Abs were inoculated, this EE effect was statistically reversed (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>).<fig id="Fig5"><label>Fig. 5</label><caption><p>The anti mammary tumor effect of an epimastigote extract (EE) is reversed by specific anti-rTcCRT Abs. A/J mice were inoculated s.c. in a supra scapular area with mammary adenocarcinoma cells (TA3-MTXR, control group) and challenged as indicated in the Figure and detailed in Materials and Methods. The EE anti mammary tumor effect is reverted by specific anti-TcCRT Abs. (One-tailed Wilcoxon signed-rank test)</p></caption><graphic xlink:href="12885_2016_2764_Fig5_HTML" id="MO5"/></fig></p></sec><sec id="Sec19"><title>Mammary tumors grown in animals alternatively treated with <italic>T. cruzi</italic> infection, EE or N-rTcCRT, display a less aggressive histological pattern</title><p>Mammary tumors, in untreated groups, showed more aggressive histological patterns, with changes at the deep dermal levels (vascularization, edema, inflammation and congestion), with areas of high tumor cell proliferation that profusely invaded the dermal layers (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6a</xref>). Notably, in these untreated animals, tumor cells displayed a less cohesive pattern, with infrequent contacts among them and with a high nucleus/cytoplasm ratio (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6b</xref>). Moreover, a high percentage of bizarre, both multinucleated or mitotic cells, was observed, as well as tumor cells that invaded the dermis and epidermis causing, in some cases, ulceration of the skin surface (Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Fig. S1A-D).<fig id="Fig6"><label>Fig. 6</label><caption><p>Mammary tumors from animals treated with either <italic>T. cruzi</italic> infection, EE or N-rTcCRT, display less aggressive histological patterns. TA3-MTXR tumor (T) extracted from representative animals: <bold>a b</bold> Non infected, control group; <bold>c d</bold>
<italic>T. cruzi</italic> infected; <bold>e f</bold>
<italic>T. cruzi</italic>- infected, inoculated with anti-rTcCRT F(ab&#x02019;)<sub>2</sub> fragments; <bold>g h</bold> Inoculated with an EE; <bold>i j</bold> Inoculated with N-rTcCRT. The following parameters were analyzed: E: Epidermis; D: Dermis layer; T: Tumor tissue (<bold>a</bold>, <bold>c</bold>, <bold>e</bold>, <bold>g</bold>, and <bold>i</bold>) and TC: Tumor cells (<bold>b</bold>, <bold>d</bold>, <bold>f</bold>, <bold>h</bold> and <bold>j</bold>)</p></caption><graphic xlink:href="12885_2016_2764_Fig6_HTML" id="MO6"/></fig></p><p>On <italic>T. cruzi</italic> infected animals, we found more conserved and differentiated tumor cells, distributed as large sheets of cells in a more compact arrangement, with bigger and vacuolated cytoplasm (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6d</xref>). These samples were less invasive towards adipose tissue and most samples presented defined and encapsulated internal margins, without subcutaneous invasion (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6c</xref>). A similar situation was observed in animals inoculated with EE and N-rTcCRT (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6g</xref>&#x02013;<xref rid="Fig6" ref-type="fig">j</xref>). However, when the animals were treated with anti-rTcCRT F(ab&#x02019;)<sub>2</sub> fragments, this pattern was not maintained and tumor histopathology was very similar to the control group (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6e</xref>&#x02013;<xref rid="Fig6" ref-type="fig">f</xref>).</p></sec></sec><sec id="Sec20"><title>Discussion</title><p>We have proposed that rTcCRT [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>] provides an important at least partial explanation of why <italic>T. cruzi</italic> experimental infection or the inoculation of parasite extracts exerts toxic effects on different tumor types, mammary adenocarcinoma among them (reviewed in [<xref ref-type="bibr" rid="CR2">2</xref>]).</p><p>We have described a 45&#x000a0;kDa&#x02009;<italic>T. cruzi</italic>, highly pleiotropic chaperone protein, TcCRT [<xref ref-type="bibr" rid="CR13">13</xref>]. rTcCRT [<xref ref-type="bibr" rid="CR13">13</xref>] is antiangiogenic because it inhibits ECs proliferation, migration and morphogenesis, in several in vitro, <italic>ex vivo</italic> and in vivo assays, in 3 species, <italic>H. s. sapiens</italic> included [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>]. Furthermore, in vivo, rTcCRT inhibits the growth of an experimental mammary adenocarcinoma, when inoculated in an area near the tumor. This effect is more potent than the one elicited by its rHuCRT counterpart [<xref ref-type="bibr" rid="CR9">9</xref>]. However, the proposal that <italic>T.cruzi</italic> infection has an antitumor effect mediated by its nTcCRT, needs a formal demonstration, as justified in the Introduction section. This important question was addressed herein. In order to causally implicate nTcCRT in the antitumor effect of <italic>T. cruzi</italic> infection, we blocked these effects, with polyclonal anti-rTcCRT Abs, in the context of the trypomastigote infection or epimastigote extract (EE) inoculation. Since angiogenesis is important for tumor development, we previously showed that these Abs neutralize the antiangiogenic effect of rTcCRT [<xref ref-type="bibr" rid="CR17">17</xref>].</p><p>We first checked whether anti-rTcCRT Abs block the chaperone binding to ECs [<xref ref-type="bibr" rid="CR9">9</xref>], since this contact is a necessary prerequisite for angiogenesis inhibition. As expected, anti-rTcCRT F(ab&#x02019;)<sub>2</sub> fragments reversed this interaction (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1a-b</xref>), as well as the antiproliferative effect reported for rTcCRT [<xref ref-type="bibr" rid="CR9">9</xref>] (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). Thus, we validated these Abs for their use in vivo.</p><p>The rationale for choosing whole anti-rTcCRT Abs or their F(ab&#x02019;)<sub>2</sub> fragments, in the experiments described below, is based on their differential Fc-dependent capacity to bind human complement C1 [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR33">33</xref>] Thus: i). Whole anti-rTcCRT Abs, upon recognizing translocated nTcCRT on trypomastigotes, will recruit host C1, a potent infectivity-promoter [<xref ref-type="bibr" rid="CR33">33</xref>]; ii). Because this Fc-dependent C1-recruiting IgG capacity is absent in F(ab&#x02019;)<sub>2</sub> fragments, these will block infectivity [<xref ref-type="bibr" rid="CR33">33</xref>]; iii). Contact of rTcCRT with C1 and/or membrane receptors, and its functional consequences, should be blocked with both whole IgG or F(ab&#x02019;)<sub>2</sub> fragments [<xref ref-type="bibr" rid="CR33">33</xref>] and, iv). nTcCRT, present in a non-infective EE [<xref ref-type="bibr" rid="CR34">34</xref>] should be also blocked by both whole IgG or F(ab&#x02019;)<sub>2</sub> fragments (Figs.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref> and <xref rid="Fig4" ref-type="fig">4</xref>, respectively).</p><p>A possible mechanism favoring the rTcCRT EC internalization [<xref ref-type="bibr" rid="CR9">9</xref>] involves its binding to Scavenger Receptors (SRs). nTcCRT has affinity for collagenous structures, thus explaining its binding to human C1, with consequent inhibition of the classical pathway of the complement system [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR33">33</xref>]. Fluid-phase Fucoidan, bearing extensive collagen-like sequences, inhibits the binding of CRT to SR-A, present on phagocytic cells [<xref ref-type="bibr" rid="CR18">18</xref>], and the internalization of rTcCRT by ECs [<xref ref-type="bibr" rid="CR9">9</xref>]. In agreement with these findings, the two types of Fucoidans used by us, inhibited the binding to ECs of both rTcCRT (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1c</xref>-<xref rid="Fig1" ref-type="fig">d</xref>) and its N-domain (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1e</xref>-<xref rid="Fig1" ref-type="fig">f</xref>).</p><p>Since SR-A1 has a high proportion of collagenous sequences [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR23">23</xref>], the possibility exists that rTcCRT exerts its action via EC internalization through this SR [<xref ref-type="bibr" rid="CR21">21</xref>&#x02013;<xref ref-type="bibr" rid="CR23">23</xref>]. The relevant signaling pathways and activated or inhibited genes are still unknown.</p><p>Since anti-rTcCRT Abs abrogated the antitumor effect of rTcCRT [<xref ref-type="bibr" rid="CR9">9</xref>&#x02013;<xref ref-type="bibr" rid="CR11">11</xref>] (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3a</xref>), it could be proposed that they should block the native parasite protein, in the context of an infection or EE inoculation.</p><p>We next asked whether antiangiogenesis has implications in the antitumor capacity of the parasite chaperone. We showed that the N-domain (antiangiogenic) [<xref ref-type="bibr" rid="CR9">9</xref>] effectively inhibited tumor development (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3b</xref>), thus opening the probability that even smaller subdomains, still to be defined, may also exert this effect.</p><p>However, the facts that, on the one hand, <italic>T. cruzi</italic> infection has an antitumor effect [<xref ref-type="bibr" rid="CR2">2</xref>&#x02013;<xref ref-type="bibr" rid="CR5">5</xref>] and, on the other, rTcCRT largely reproduces it [<xref ref-type="bibr" rid="CR9">9</xref>], does not necessarily mean that, during infection, nTcCRT is indeed a valid mediator of this effect. As expected, anti-rTcCRT (Fab&#x02019;)<sub>2</sub> Abs inhibited this antitumor effect (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>), thus formally involving nTcCRT.</p><p>Roskin and Klyuyeva injected, directly into the tumor site, parasite lysates with antitumor effects (reviewed in [<xref ref-type="bibr" rid="CR2">2</xref>]). Epimastigotes, non-infective <italic>T. cruzi</italic> forms, express marginal levels of TcCRT on their external membrane [<xref ref-type="bibr" rid="CR31">31</xref>], although intracellular levels of the chaperone are apparently normal. TcCRT translocation in these parasite forms is apparently deficient [<xref ref-type="bibr" rid="CR31">31</xref>] and may explain, at least partly, their incapacity to infect cells. As expected, EE delayed tumor growth and, in some animals, complete tumor regression was observed (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>). A recent report [<xref ref-type="bibr" rid="CR6">6</xref>] shows similar results, in a rat model. Indeed, they reproduce the antitumor effects of <italic>T. cruzi</italic> epimastigote lysates and found that they trigger cytotoxic responses against tumors, with activation of both CD4<sup>+</sup> and CD8<sup>+</sup> T cells. These extracts elicited the production of antibodies that cross reacted with human colon and breast cancer tissue samples. Given our results, most likely the antitumor effect observed by these authors should be significantly and specifically inhibited by our anti-rTcCRT Abs, as shown in Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>. In synthesis and in agreement with the previous results, <italic>T. cruzi</italic> infection effects on the normal course in a mammary tumor development is largely nTcCRT-dependent.</p><p>Representative tumor histology indicated decreased tumor malignancy, in particular at 28 d.p.i. Noteworthy, in <italic>T. cruzi</italic> infected animals, or EE or N-TcCRT inoculated ones, tumors were encapsulated and less invasive (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6c</xref>-<xref rid="Fig6" ref-type="fig">d</xref>, <xref rid="Fig6" ref-type="fig">g</xref>&#x02013;<xref rid="Fig6" ref-type="fig">j</xref>). In agreement with the previous results, when, in infected animals, TcCRT was blocked with F(ab&#x02019;)<sub>2</sub> anti- TcCRT Ab fragments, more aggressive tumor patterns are observed (similar to the control group) (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6a</xref>-<xref rid="Fig6" ref-type="fig">b</xref>, as compared to Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6e</xref>-<xref rid="Fig6" ref-type="fig">f</xref>).</p><p>Altogether, these results support the antitumor activity of nTcCRT, although we cannot completely rule out the involvement of other parasite molecules.</p><p>The use of a recombinant nonpathogenic <italic>T. cruzi</italic> clone as a vaccine vector to induce T-cell-mediated immunity has been reported [<xref ref-type="bibr" rid="CR35">35</xref>]. These authors show that transgenic parasites, expressing a cancer testis antigen, elicit human antigen-specific T-cell responses in vitro and protection against a murine melanoma in vivo. Given our results, in this work it would have been important to define whether the nonpathogenic <italic>T. cruzi</italic> clone used by these authors translocates-externalizes its CRT. As mentioned above, non-infective epimastigotes are strongly impaired in their capacity to translocate this chaperone [<xref ref-type="bibr" rid="CR31">31</xref>]. Moreover, hemiallelic <italic>TcCRT</italic> KO, wild type and transgenic parasites respectively carrying one, two and three <italic>TcCRT</italic> gene copies, express increasing levels of the protein. As expected, these facts positively correlate with increased in vitro resistance to human complement, as well as with infectivity [<xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR37">37</xref>]. We will soon test these three clones in their experimental capacity to control tumor growth.</p><p>Although we cannot rule out a role of antitumor innate immunity in the results presented herein, during infection TcCRT seems to be playing a direct immunogenic role in the induction of specific anamnestic immunity against the experimental mammary tumor tested. Human complement component C1 plays an extremely important adjuvant role by generating potent opsonizing signals on the parasite [<xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR38">38</xref>], thus increasing their infectivity. Preliminary results from our laboratory, show increased numbers of CD8<sup>+</sup> and CD4<sup>+</sup> lymphocytes in rTcCRT-treated mammary tumor bearing mice. Again, concomitant important decreases in tumor sizes were observed (Gallardo et al., 2016, unpublished).</p><p>In synthesis, as depicted in Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7</xref>, we can propose that <italic>T. cruzi</italic> infection mediates key alterations in the tumor cell microenvironment that may lead to an adaptive immune response, with significant antitumor effects. Once in the circulation, <italic>T. cruzi</italic> must swiftly invade ECs. Translocated-exteriorized TcCRT [<xref ref-type="bibr" rid="CR15">15</xref>] will recruit and inactivate plasma complement C1. This will allow the parasite to contact ECs via cC1qR [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR20">20</xref>]. Otherwise, the chaperone protein could interact directly with SR-A1 on ECs [<xref ref-type="bibr" rid="CR21">21</xref>&#x02013;<xref ref-type="bibr" rid="CR23">23</xref>]. Both pathways may lead to antiangiogenesis and generate a stressful environment where tumor cells will externalize their CRT, as previously shown with other stressing agents, such as antracyclins [<xref ref-type="bibr" rid="CR39">39</xref>]. Complement C1 recruitment and increased tumor cell phagocytosis by dendritic cells will follow.<fig id="Fig7"><label>Fig. 7</label><caption><p>Proposed extracellular mechanisms explaining, at least partially, the in vivo antitumor effect of <italic>T. cruzi</italic> infection. <bold>a</bold> TcCRT antiangiogenic effect: (1) <italic>T. cruzi</italic> exposes its CRT on the parasite surface, followed by C1 recruitment and inactivation; (2) On the ECs membrane, a trimolecular synapse is formed by cC1qR-C1-TcCRT, from EC, host and parasite origins, respectively; (3) SRs present on ECs bind TcCRT. The last two mechanisms, could activate antiangiogenic signals on ECs, with consequent inhibition of angiogenesis (4). Decreased nutrients and oxygen supply may constitute a stressful environment for the tumor, CRT will be exteriorized and C1 recruited (5). Dendritic antigen presenting cells (APCs), through their cC1qRs will recognize, internalize and process these tumor cells (6) on their way to local lymph nodes (7). <bold>b</bold> Possible nTcCRT-mediated induction of an anamnestic antitumor immune response: Parasite translocated TcCRT binds to the tumor cell (8), with subsequent capture of host C1 (9). This C1 will be recognized by cC1qR present on APCs, followed by internalization of this complex (10). Among many other possibilities, APCs will cross-process TcCRT and specific peptides from this parasite protein will be loaded onto MHC I molecules. APCs will enter the regional lymph node and present these nTcCRT-specific peptides to cytotoxic T lymphocytes, thus leading to their activation (11). These CD8<sup>+</sup> cytotoxic T lymphocytes will leave the lymph node and kill tumor cells that also present TcCRT derived peptides (12)</p></caption><graphic xlink:href="12885_2016_2764_Fig7_HTML" id="MO7"/></fig></p><p>On the other hand, an adaptive immune response may involve both highly immunogenic rTcCRT, and its native counterpart, this one present on the membrane of infecting trypomastigotes [<xref ref-type="bibr" rid="CR15">15</xref>] or in EE [<xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR34">34</xref>]. In any case, the chaperone protein should reach the surface of both endotheliocytes and tumor cells, thus generating a site for C1 binding. Tumor cells, thus opsonized should be phagocytized by dendritic cells. Upon arrival to the regional lymph nodes, these dendritic cells will present antigenic peptides derived from TcCRT, thus activating cytotoxic T lymphocytes. Whether tumor cells can cross-present peptides derived from endocytosed TcCRT to cytotoxic T cells, is a matter of current research in our laboratory. Activated cytotoxic T cells should then return to the tumor site and act against neoplastic tumor cells in both, primary, as well as in metastatic foci (Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7</xref>), a mechanism already shown for whole EE [<xref ref-type="bibr" rid="CR40">40</xref>].</p><p>Because about 90&#x000a0;% identity exists among mammal CRTs, while TcCRT is only 50&#x000a0;% identical, the latter is highly immunogenic in infected humans [<xref ref-type="bibr" rid="CR34">34</xref>] and in animals [<xref ref-type="bibr" rid="CR41">41</xref>]. Interestingly, TcCRT sequence is closer to plant CRT (e.g. <italic>Arabidopsis thaliana</italic>) than to mammal CRT (Weinberger et al., 2016, unpublished), thus explaining its high immunogenicity. The parasite protein (recombinant or native) bound to mammal tumor cells, could thus provide strong immunogenic signals that reveal the tumor presence to an otherwise tolerant immune system.</p><p>In a large set of experimental animals treated with rTcCRT, no clinical deleterious effects have been detected by standard clinical veterinary criteria. rTcCRT, or derived domains, are interesting immunological tools to be considered in more advanced preclinical trials (e.g. rTcCRT and C1 binding to human mammary tumor cell lines and its opsonizing consequences).</p></sec><sec id="Sec21"><title>Conclusions</title><p>Translocated/externalized native <italic>Trypanosoma cruzi</italic> calreticulin is responsible for at least an important part of the anti mammary tumor effect of the experimental infection with this parasite. Highly immunogenic recombinant TcCRT largely reproduces this effect mainly by capturing complement C1 on the tumor cell surface, where a danger opsonizing signal is thus generated. Altogether, these results allow us to propose that an extremely relevant alteration in the tumor microenvironment is thus accomplished. The presence of the tumor cells is thus revealed to the immune system, with likely generation of an anamnestic systemic immune response. These results identify recombinant TcCRT or domains thereof, as interesting tools for further preclinical studies in mammary cancer (i.e. tissue specificity of the parasite chaperone, signal transduction pathways involved, rTcCRT opsonization of human tumor cell lines).</p></sec></body><back><app-group><app id="App1"><sec id="Sec22"><title>Additional file</title><p><media position="anchor" xlink:href="12885_2016_2764_MOESM1_ESM.tif" id="MOESM1"><label>Additional file 1: Fig. S1.</label><caption><p>Quantitative analysis of necrotic area (A), mitosis index (B) ulceration (C) and bizarre cells (D) in slides of tumors from different groups stained with hematoxylin and eosin. The percentages (A, C) or absolute numbers (B, D) were calculated in triplicates in 10 fields with a 400&#x000d7; magnification. (One-Way ANOVA and a <italic>post</italic>-<italic>hoc</italic> Bonferroni&#x02019;s multiple comparison test). (TIF 2723&#x000a0;kb)</p></caption></media></p></sec></app></app-group><glossary><title>Abbreviations</title><def-list><def-item><term>Abs</term><def><p>Antibodies</p></def></def-item><def-item><term>BrdU</term><def><p>Bromodeoxyuridine</p></def></def-item><def-item><term>cC1qR</term><def><p>C1 receptor</p></def></def-item><def-item><term>CRT</term><def><p>Calreticulin</p></def></def-item><def-item><term>EC</term><def><p>Endothelial cell</p></def></def-item><def-item><term>EE</term><def><p>Epimastigote extract</p></def></def-item><def-item><term>ER</term><def><p>Endoplasmic reticulum</p></def></def-item><def-item><term>FBS</term><def><p>Fetal bovine serum</p></def></def-item><def-item><term>F-rTcCRT</term><def><p>FITC-coupled recombinant <italic>trypanosoma cruzi</italic> calreticulin</p></def></def-item><def-item><term>HuCRT</term><def><p>Human calreticulin</p></def></def-item><def-item><term>MHC I</term><def><p>Major histocompatibility complex class I</p></def></def-item><def-item><term>MmCRT</term><def><p>Murine calreticulin</p></def></def-item><def-item><term>N-rTcCRT</term><def><p>Recombinant N-domain of <italic>trypanosoma cruzi</italic> calreticulin</p></def></def-item><def-item><term>nTcCRT</term><def><p>Native <italic>trypanosoma cruzi</italic> calreticulin</p></def></def-item><def-item><term>rTcCRT</term><def><p>Recombinant <italic>trypanosoma cruzi</italic> calreticulin</p></def></def-item><def-item><term>SR</term><def><p>Scavenger receptor</p></def></def-item><def-item><term><italic>T. cruzi</italic></term><def><p><italic>Trypanosoma cruzi</italic></p></def></def-item><def-item><term>TA3-MTXR</term><def><p>Methotrexate multiresistant mammary adenocarcinoma cell line</p></def></def-item><def-item><term>TcCRT</term><def><p><italic>Trypanosoma cruzi</italic> calreticulin</p></def></def-item></def-list></glossary><ack><title>Acknowledgements</title><p>We are grateful to Ruth Mora, Juana Orellana, Nancy Fabres, Iv&#x000e1;n Contreras and Miguel Sep&#x000fa;lveda, for their excellent expert technical assistance.</p><sec id="FPar1"><title>Funding</title><p>This study was supported by the following Chilean Public Research Grants: CONICYT-Chile, Bicentennial Associative Research 112 (AF), Regular Fondecyt 1130099 Project (AF) and CONICYT Doctoral Fellowship (PAC).</p></sec><sec id="FPar2"><title>Availability of data and materials</title><p>The datasets generated and/or analyzed during the current study are available from the corresponding author on reasonable request.</p></sec><sec id="FPar3"><title>Authors&#x02019; contributions</title><p>PAC: Experimental execution, collection and assembly of data, data analysis and interpretation and manuscript writing. JPB: Data analysis, interpretation and manuscript writing. CR: Data analysis, interpretation and assembly. IM: Production of reagents and data analysis. LAG: Data analysis and interpretation. CG: Histopathological analysis and their interpretation. GR: Production of F(ab&#x02019;)<sub>2</sub> modified antibodies and data analysis. JF: Production of TA3-MTXR murine mammary tumor cell line and data discussion. AF: Analysis, interpretation of data, manuscript writing, drafting, revision for intellectual content and contributed with financial support. All authors read and approved the final version of this manuscript.</p></sec><sec id="FPar4"><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec id="FPar5"><title>Consent for publication</title><p>Not applicable.</p></sec><sec id="FPar6"><title>Ethics approval and consent to participate</title><p>This study was performed strictly observing the guidelines established by the Bioethics Committee, Faculty of Medicine, University of Chile, with approval number 0531 FMUCHF, for the project FONDECYT/CHILE, 1130099 (<italic>Trypanosoma cruzi</italic> Calreticulin, by virtue of its Anti-Angiogenic Properties, Inhibits Tumor Growth in Experimental models).</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clayton</surname><given-names>J</given-names></name></person-group><article-title>Chagas disease 101</article-title><source>Nature</source><year>2010</year><volume>465</volume><fpage>S4</fpage><lpage>S5</lpage><pub-id pub-id-type="doi">10.1038/nature09220</pub-id><?supplied-pmid 20571553?><pub-id pub-id-type="pmid">20571553</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><mixed-citation publication-type="other">Ram&#x000ed;rez G, Abello P, Ferreira A. Is the Antitumor Property of <italic>Trypanosoma cruzi</italic> Infection Mediated by Its Calreticulin?. 2016; Front Immunol. http://dx.doi.org/10.3389/fimmu.2016.00268.</mixed-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kallinikova</surname><given-names>VD</given-names></name><name><surname>Matekin</surname><given-names>PV</given-names></name><name><surname>Ogloblina</surname><given-names>TA</given-names></name><name><surname>Leikina</surname><given-names>MI</given-names></name><name><surname>Kononenko</surname><given-names>AF</given-names></name><name><surname>Sokolova</surname><given-names>MN</given-names></name><etal/></person-group><article-title>Anticancer Properties of Parasite Flagellate Protozoan <italic>Trypanosoma cruzi</italic> Chagas, 1909</article-title><source>Biol Bull</source><year>2001</year><volume>28</volume><fpage>244</fpage><lpage>255</lpage><pub-id pub-id-type="doi">10.1023/A:1016636419597</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><mixed-citation publication-type="other">Krementsov N. The Cure. A story of cancer and politics from the annals of the Cold War. Chicago: The University of Chicago Press. 2002;p.30&#x02013;2.</mixed-citation></ref><ref id="CR5"><label>5.</label><mixed-citation publication-type="other">Krementsov N. The cure. A story of cancer and politics from the annals of the Cold War. Chicago: The University of Chicago Press. 2002;p.198&#x02013;206.</mixed-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ubillos</surname><given-names>L</given-names></name><name><surname>Freire</surname><given-names>T</given-names></name><name><surname>Berriel</surname><given-names>E</given-names></name><name><surname>Chiribao</surname><given-names>ML</given-names></name><name><surname>Chiale</surname><given-names>C</given-names></name><name><surname>Festari</surname><given-names>MF</given-names></name><etal/></person-group><article-title><italic>Trypanosoma cruzi</italic> extracts elicit protective immune response against chemically induced colon and mammary cancers</article-title><source>Int J Cancer</source><year>2016</year><volume>138</volume><fpage>1719</fpage><lpage>1731</lpage><pub-id pub-id-type="doi">10.1002/ijc.29910</pub-id><?supplied-pmid 26519949?><pub-id pub-id-type="pmid">26519949</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Batmonkh</surname><given-names>Z</given-names></name><name><surname>Kallinikova</surname><given-names>VD</given-names></name><name><surname>Pakhorukova</surname><given-names>LV</given-names></name><name><surname>Kravtsov</surname><given-names>EG</given-names></name><name><surname>Karpenko</surname><given-names>LP</given-names></name><name><surname>Dalin</surname><given-names>MV</given-names></name></person-group><article-title>In vivo anticancer activity of lysates from <italic>Trypanosoma cruzi</italic> of different genetic groups</article-title><source>Bull Exp Biol Med</source><year>2006</year><volume>142</volume><fpage>470</fpage><lpage>473</lpage><pub-id pub-id-type="doi">10.1007/s10517-006-0395-6</pub-id><?supplied-pmid 17415440?><pub-id pub-id-type="pmid">17415440</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morillo</surname><given-names>A</given-names></name><name><surname>Gonz&#x000e1;lez</surname><given-names>E</given-names></name><name><surname>Larrarte</surname><given-names>S</given-names></name><name><surname>Ibarra</surname><given-names>A</given-names></name><name><surname>Alvarez</surname><given-names>C</given-names></name><name><surname>Colmenares</surname><given-names>V</given-names></name><etal/></person-group><article-title><italic>Trypanosoma cruzi</italic> infection decreases malignant melanoma development and increases survival in C57BL/6 mice</article-title><source>Invest Clin</source><year>2014</year><volume>55</volume><fpage>227</fpage><lpage>237</lpage><pub-id pub-id-type="pmid">25272522</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>L&#x000f3;pez</surname><given-names>NC</given-names></name><name><surname>Valck</surname><given-names>C</given-names></name><name><surname>Ram&#x000ed;rez</surname><given-names>G</given-names></name><name><surname>Rodr&#x000ed;guez</surname><given-names>M</given-names></name><name><surname>Ribeiro</surname><given-names>C</given-names></name><name><surname>Orellana</surname><given-names>J</given-names></name><etal/></person-group><article-title>Antiangiogenic and antitumor effects of <italic>Trypanosoma cruzi</italic> Calreticulin</article-title><source>PLoS Negl Trop Dis</source><year>2010</year><volume>4</volume><fpage>e730</fpage><pub-id pub-id-type="doi">10.1371/journal.pntd.0000730</pub-id><?supplied-pmid 20625551?><pub-id pub-id-type="pmid">20625551</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ram&#x000ed;rez</surname><given-names>G</given-names></name><name><surname>Aguilar</surname><given-names>L</given-names></name><name><surname>Valck</surname><given-names>C</given-names></name><name><surname>Abello</surname><given-names>P</given-names></name><name><surname>Ferreira</surname><given-names>A</given-names></name></person-group><article-title>Is it all That Bad When Living with an Intracellular Protozoan? The Role of <italic>Trypanosoma cruzi</italic> Calreticulin in Angiogenesis and Tumor Growth</article-title><source>Front Oncol</source><year>2015</year><volume>4</volume><fpage>382</fpage><pub-id pub-id-type="pmid">25629005</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aguilar</surname><given-names>L</given-names></name><name><surname>Lobos</surname><given-names>L</given-names></name><name><surname>Rosas</surname><given-names>C</given-names></name><name><surname>Vallejos</surname><given-names>G</given-names></name><name><surname>Falc&#x000f3;n</surname><given-names>C</given-names></name><name><surname>Sosoniuk</surname><given-names>E</given-names></name><etal/></person-group><article-title>Human Survivin and <italic>Trypanosoma cruzi</italic> Calreticulin Act in Synergy against a Murine Melanoma In Vivo</article-title><source>PLoS One</source><year>2014</year><volume>9</volume><fpage>e95457</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0095457</pub-id><pub-id pub-id-type="pmid">24755644</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramirez</surname><given-names>G</given-names></name><name><surname>Valck</surname><given-names>C</given-names></name><name><surname>Aguilar</surname><given-names>L</given-names></name><name><surname>Kemmerling</surname><given-names>U</given-names></name><name><surname>L&#x000f3;pez-Munoz</surname><given-names>R</given-names></name><name><surname>Cabrera</surname><given-names>G</given-names></name><etal/></person-group><article-title>Roles of <italic>Trypanosoma cruzi</italic> calreticulin in parasite-host interactions and in tumor growth</article-title><source>Mol Immunol</source><year>2012</year><volume>52</volume><fpage>133</fpage><lpage>140</lpage><pub-id pub-id-type="doi">10.1016/j.molimm.2012.05.006</pub-id><?supplied-pmid 22673211?><pub-id pub-id-type="pmid">22673211</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramos</surname><given-names>R</given-names></name><name><surname>Juri</surname><given-names>M</given-names></name><name><surname>Ramos</surname><given-names>A</given-names></name><name><surname>Hoecker</surname><given-names>G</given-names></name><name><surname>Lavandero</surname><given-names>S</given-names></name><name><surname>Pena</surname><given-names>P</given-names></name><etal/></person-group><article-title>An immunogenetically defined and immunodominant <italic>Trypanosoma cruzi</italic> antigen</article-title><source>Am J Trop Med Hyg</source><year>1991</year><volume>44</volume><fpage>314</fpage><lpage>322</lpage><?supplied-pmid 2035753?><pub-id pub-id-type="pmid">2035753</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aguillon</surname><given-names>JC</given-names></name><name><surname>Ferreira</surname><given-names>L</given-names></name><name><surname>Perez</surname><given-names>C</given-names></name><name><surname>Colombo</surname><given-names>A</given-names></name><name><surname>Molina</surname><given-names>MC</given-names></name><name><surname>Wallace</surname><given-names>A</given-names></name><etal/></person-group><article-title>Tc45, a dimorphic <italic>Trypanosoma cruzi</italic> immunogen with variable chromosomal localization, is calreticulin</article-title><source>Am J Trop</source><year>2000</year><volume>63</volume><fpage>306</fpage><lpage>312</lpage></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferreira</surname><given-names>V</given-names></name><name><surname>Valck</surname><given-names>C</given-names></name><name><surname>S&#x000e1;nchez</surname><given-names>G</given-names></name><name><surname>Gingras</surname><given-names>A</given-names></name><name><surname>Tzima</surname><given-names>S</given-names></name><name><surname>Molina</surname><given-names>MC</given-names></name><etal/></person-group><article-title>The classical activation pathway of the human complement system is specifically inhibited by calreticulin from <italic>Trypanosoma cruzi</italic></article-title><source>J Immunol</source><year>2004</year><volume>172</volume><fpage>3042</fpage><lpage>3050</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.172.5.3042</pub-id><?supplied-pmid 14978109?><pub-id pub-id-type="pmid">14978109</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><mixed-citation publication-type="other">Molina MC, Ferreira V, Valck C, Aguilar L, Orellana J, Rojas A, et al<italic>.</italic> An in vivo role for <italic>Trypanosoma cruzi</italic> calreticulin in antiangiogenesis. Mol Biochem Parasitol. 2005;140:133&#x02013;40.</mixed-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Toledo</surname><given-names>V</given-names></name><name><surname>Ramirez</surname><given-names>G</given-names></name><name><surname>Valck</surname><given-names>C</given-names></name><name><surname>L&#x000f3;pez</surname><given-names>N</given-names></name><name><surname>Ribeiro</surname><given-names>CH</given-names></name><name><surname>Maldonado</surname><given-names>I</given-names></name><etal/></person-group><article-title>Comparative in vivo antiangiogenic effects of calreticulin from <italic>Trypanosoma cruzi</italic> and Homosapiens sapiens</article-title><source>Biol Res</source><year>2010</year><volume>43</volume><fpage>287</fpage><lpage>289</lpage><pub-id pub-id-type="doi">10.4067/S0716-97602010000300004</pub-id><?supplied-pmid 21249299?><pub-id pub-id-type="pmid">21249299</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berwin</surname><given-names>B</given-names></name><name><surname>Hart</surname><given-names>JP</given-names></name><name><surname>Rice</surname><given-names>S</given-names></name><name><surname>Gass</surname><given-names>C</given-names></name><name><surname>Pizzo</surname><given-names>SV</given-names></name><name><surname>Post</surname><given-names>SR</given-names></name><etal/></person-group><article-title>Scavenger receptor-A mediates gp96/GRP94 and calreticulin internalization by antigen-presenting cells</article-title><source>EMBO J</source><year>2003</year><volume>22</volume><fpage>6127</fpage><lpage>6136</lpage><pub-id pub-id-type="doi">10.1093/emboj/cdg572</pub-id><?supplied-pmid 14609958?><pub-id pub-id-type="pmid">14609958</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><mixed-citation publication-type="other">Eggleton P, Tenner AJ, Reid KB. C1q receptors. Clin Exp Immunol. 2000;3:406&#x02013;12.</mixed-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van den Berg</surname><given-names>RH</given-names></name><name><surname>Faber-Krol</surname><given-names>MC</given-names></name><name><surname>Sim</surname><given-names>RB</given-names></name><name><surname>Daha</surname><given-names>MR</given-names></name></person-group><article-title>The first subcomponent of complement, C1q, triggers the production of IL-8, IL-6, and monocyte chemoattractant peptide-1 by human umbilical vein endothelial cells</article-title><source>J Immunol</source><year>1998</year><volume>161</volume><fpage>6924</fpage><lpage>6930</lpage><?supplied-pmid 9862726?><pub-id pub-id-type="pmid">9862726</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adachi</surname><given-names>H</given-names></name><name><surname>Tsujimoto</surname><given-names>M</given-names></name><name><surname>Arai</surname><given-names>H</given-names></name><name><surname>Inoue</surname><given-names>K</given-names></name></person-group><article-title>Expression cloning of a novel scavenger receptor from human endothelial cells</article-title><source>J Biol Chem</source><year>1997</year><volume>272</volume><fpage>31217</fpage><lpage>31220</lpage><pub-id pub-id-type="doi">10.1074/jbc.272.50.31217</pub-id><?supplied-pmid 9395444?><pub-id pub-id-type="pmid">9395444</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><mixed-citation publication-type="other">Zani IA, Stephen SL, Mughal NA, Russell D, Homer-Vanniasinkam S, Wheatcroft SB, et al. Scavenger receptor structure and function in health and disease. Cells. 2015;4:178&#x02013;01.</mixed-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Canton</surname><given-names>J</given-names></name><name><surname>Neculai</surname><given-names>D</given-names></name><name><surname>Grinstein</surname><given-names>S</given-names></name></person-group><article-title>Scavenger receptors in homeostasis and immunity</article-title><source>Nat Rev Immunol</source><year>2013</year><volume>13</volume><fpage>621</fpage><lpage>634</lpage><pub-id pub-id-type="doi">10.1038/nri3515</pub-id><?supplied-pmid 23928573?><pub-id pub-id-type="pmid">23928573</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Michalak</surname><given-names>M</given-names></name><name><surname>Groenendyk</surname><given-names>J</given-names></name><name><surname>Szabo</surname><given-names>E</given-names></name><name><surname>Gold</surname><given-names>LI</given-names></name><name><surname>Opas</surname><given-names>M</given-names></name></person-group><article-title>Calreticulin, a multiprocess calcium-buffering chaperone of the endoplasmic reticulum</article-title><source>Biochem J</source><year>2009</year><volume>417</volume><fpage>651</fpage><lpage>666</lpage><pub-id pub-id-type="doi">10.1042/BJ20081847</pub-id><?supplied-pmid 19133842?><pub-id pub-id-type="pmid">19133842</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aguilar</surname><given-names>L</given-names></name><name><surname>Ramirez</surname><given-names>G</given-names></name><name><surname>Valck</surname><given-names>C</given-names></name><name><surname>Molina</surname><given-names>MC</given-names></name><name><surname>Rojas</surname><given-names>A</given-names></name><name><surname>Schwaeble</surname><given-names>W</given-names></name><etal/></person-group><article-title>F(ab)<sub>2</sub> antibody fragments against <italic>Trypanosoma cruzi</italic> calreticulin inhibit its interaction with the first component of human complement</article-title><source>Biol Res</source><year>2005</year><volume>38</volume><fpage>187</fpage><lpage>195</lpage><pub-id pub-id-type="doi">10.4067/S0716-97602005000200008</pub-id><?supplied-pmid 16238097?><pub-id pub-id-type="pmid">16238097</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahn</surname><given-names>K</given-names></name><name><surname>Pan</surname><given-names>S</given-names></name><name><surname>Beningo</surname><given-names>K</given-names></name><name><surname>Hupe</surname><given-names>D</given-names></name></person-group><article-title>A permanent human cell line (EA.hy926) preserves the characteristics of endothelin converting enzyme from primary human umbilical vein endothelial cells</article-title><source>Life Sci</source><year>1995</year><volume>26</volume><fpage>2331</fpage><lpage>2341</lpage><pub-id pub-id-type="doi">10.1016/0024-3205(95)00227-W</pub-id><pub-id pub-id-type="pmid">7791520</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morello</surname><given-names>A</given-names></name><name><surname>Pavani</surname><given-names>M</given-names></name><name><surname>Garbarino</surname><given-names>JA</given-names></name><name><surname>Chamy</surname><given-names>MC</given-names></name><name><surname>Frey</surname><given-names>C</given-names></name><name><surname>Mancilla</surname><given-names>J</given-names></name><etal/></person-group><article-title>Effects and mode of action of 1,4-naphthoquinones isolated from Calceolaria sessilis on tumoral cells and Trypanosoma parasites</article-title><source>Comp Biochem Physiol C Pharmacol Toxicol Endocrinol</source><year>1995</year><volume>112</volume><fpage>119</fpage><lpage>128</lpage><pub-id pub-id-type="doi">10.1016/0742-8413(95)02003-9</pub-id><?supplied-pmid 8788584?><pub-id pub-id-type="pmid">8788584</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pavani</surname><given-names>M</given-names></name><name><surname>Fones</surname><given-names>E</given-names></name><name><surname>Oksenberg</surname><given-names>D</given-names></name><name><surname>Garcia</surname><given-names>M</given-names></name><name><surname>Hernandez</surname><given-names>C</given-names></name><name><surname>Cordano</surname><given-names>G</given-names></name><etal/></person-group><article-title>Inhibition of tumoral cell respiration and growth by nordihydroguaiaretic acid</article-title><source>Biochem Pharmacol</source><year>1994</year><volume>48</volume><fpage>1935</fpage><lpage>1942</lpage><pub-id pub-id-type="doi">10.1016/0006-2952(94)90592-4</pub-id><?supplied-pmid 7986205?><pub-id pub-id-type="pmid">7986205</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Festing</surname><given-names>MF</given-names></name><name><surname>Altman</surname><given-names>DG</given-names></name></person-group><article-title>Guidelines for the design and statistical analysis of experiments using laboratory animals</article-title><source>ILAR J</source><year>2002</year><volume>43</volume><fpage>244</fpage><lpage>258</lpage><pub-id pub-id-type="doi">10.1093/ilar.43.4.244</pub-id><?supplied-pmid 12391400?><pub-id pub-id-type="pmid">12391400</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maya</surname><given-names>JD</given-names></name><name><surname>Repetto</surname><given-names>Y</given-names></name><name><surname>Agosin</surname><given-names>M</given-names></name><name><surname>Ojeda</surname><given-names>JM</given-names></name><name><surname>Tellez</surname><given-names>R</given-names></name><name><surname>Gaule</surname><given-names>C</given-names></name><etal/></person-group><article-title>Effects of nifurtimox and benznidazole upon glutathione and trypanothione content in epimastigote, trypomastigote and amastigote forms of <italic>Trypanosoma cruzi</italic></article-title><source>Mol Biochem Parasitol</source><year>1997</year><volume>86</volume><fpage>101</fpage><lpage>106</lpage><?supplied-pmid 9178272?><pub-id pub-id-type="pmid">9178272</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sosoniuk</surname><given-names>E</given-names></name><name><surname>Vallejos</surname><given-names>G</given-names></name><name><surname>Kenawy</surname><given-names>H</given-names></name><name><surname>Gaboriaud</surname><given-names>C</given-names></name><name><surname>Thielens</surname><given-names>N</given-names></name><name><surname>Fujita</surname><given-names>T</given-names></name><etal/></person-group><article-title><italic>Trypanosoma cruzi</italic> calreticulin inhibits the complement lectin pathway activation by direct interaction with L-Ficolin</article-title><source>Mol Immunol</source><year>2014</year><volume>60</volume><fpage>80</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1016/j.molimm.2014.03.014</pub-id><?supplied-pmid 24769495?><pub-id pub-id-type="pmid">24769495</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><mixed-citation publication-type="other">Gonz&#x000e1;lez A, Valck C, S&#x000e1;nchez G, H&#x000e4;rtel S, Mansilla J, Ram&#x000ed;rez G, et al. <italic>Trypanosoma cruzi</italic> calreticulin topographical variations in parasites infecting murine macrophages. Am J Trop Med Hyg. 2015;92:887-97.</mixed-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ram&#x000ed;rez</surname><given-names>G</given-names></name><name><surname>Valck</surname><given-names>C</given-names></name><name><surname>Molina</surname><given-names>MC</given-names></name><name><surname>Ribeiro</surname><given-names>CH</given-names></name><name><surname>L&#x000f3;pez</surname><given-names>N</given-names></name><name><surname>S&#x000e1;nchez</surname><given-names>G</given-names></name><etal/></person-group><article-title>A <italic>Trypanosoma cruzi</italic> calreticulin: A novel virulence factor that binds complement C1 on the parasite surface and promotes infectivity</article-title><source>Immunobiology</source><year>2011</year><volume>216</volume><fpage>265</fpage><lpage>273</lpage><pub-id pub-id-type="doi">10.1016/j.imbio.2010.04.001</pub-id><?supplied-pmid 20472323?><pub-id pub-id-type="pmid">20472323</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aguillon</surname><given-names>JC</given-names></name><name><surname>Harris</surname><given-names>R</given-names></name><name><surname>Molina</surname><given-names>MC</given-names></name><name><surname>Colombo</surname><given-names>A</given-names></name><name><surname>Cortes</surname><given-names>C</given-names></name><name><surname>Hermosilla</surname><given-names>T</given-names></name><etal/></person-group><article-title>Recognition of an immunogenetically selected <italic>Trypanosoma cruzi</italic> antigen by seropositive chagasic human sera</article-title><source>Acta Trop</source><year>1997</year><volume>63</volume><fpage>159</fpage><lpage>166</lpage><pub-id pub-id-type="doi">10.1016/S0001-706X(96)00619-5</pub-id><?supplied-pmid 9088429?><pub-id pub-id-type="pmid">9088429</pub-id></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Junqueira</surname><given-names>C</given-names></name><name><surname>Santos</surname><given-names>LI</given-names></name><name><surname>Galv&#x000e3;o-Filho</surname><given-names>B</given-names></name><name><surname>Teixeira</surname><given-names>SM</given-names></name><name><surname>Rodrigues</surname><given-names>FG</given-names></name><name><surname>Darocha</surname><given-names>WD</given-names></name><etal/></person-group><article-title><italic>Trypanosoma cruzi</italic> as an effective cancer antigen delivery vector</article-title><source>Proc Natl Acad Sci U S A</source><year>2011</year><volume>108</volume><fpage>19695</fpage><lpage>19700</lpage><pub-id pub-id-type="doi">10.1073/pnas.1110030108</pub-id><?supplied-pmid 22114198?><pub-id pub-id-type="pmid">22114198</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>S&#x000e1;nchez</surname><given-names>FJ</given-names></name><name><surname>P&#x000e9;rez</surname><given-names>C</given-names></name><name><surname>Zago</surname><given-names>MP</given-names></name><name><surname>Labriola</surname><given-names>C</given-names></name><name><surname>Ferreira</surname><given-names>A</given-names></name><name><surname>Basombr&#x000ed;o</surname><given-names>M&#x000c1;</given-names></name></person-group><article-title><italic>Trypanosoma cruzi</italic> carrying a monoallelic deletion of the calreticulin (TcCRT) gene are susceptible tocomplement mediated killing and defective in their metacyclogenesis</article-title><source>Mol Immunol</source><year>2013</year><volume>53</volume><fpage>198</fpage><lpage>205</lpage><pub-id pub-id-type="doi">10.1016/j.molimm.2012.08.001</pub-id><pub-id pub-id-type="pmid">22954747</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>S&#x000e1;nchez</surname><given-names>FJ</given-names></name><name><surname>P&#x000e9;rez</surname><given-names>C</given-names></name><name><surname>Ram&#x000ed;rez</surname><given-names>G</given-names></name><name><surname>Uncos</surname><given-names>AD</given-names></name><name><surname>Zago</surname><given-names>MP</given-names></name><name><surname>Cimino</surname><given-names>RO</given-names></name><etal/></person-group><article-title>A monoallelic deletion of the TcCRT gene increases the attenuation of a cultured <italic>Trypanosoma cruzi</italic> strain, protecting against an in vivo virulent challenge</article-title><source>PLoS Negl Trop Dis</source><year>2014</year><volume>13</volume><issue>8</issue><fpage>e2696</fpage><pub-id pub-id-type="doi">10.1371/journal.pntd.0002696</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Valck</surname><given-names>C</given-names></name><name><surname>Ramirez</surname><given-names>G</given-names></name><name><surname>L&#x000f3;pez</surname><given-names>N</given-names></name><name><surname>Ribeiro</surname><given-names>CH</given-names></name><name><surname>Maldonado</surname><given-names>I</given-names></name><name><surname>Sanchez</surname><given-names>G</given-names></name><etal/></person-group><article-title>Molecular mechanisms involved in the inactivation of the first component of human complement by <italic>Trypanosoma cruzi</italic> calreticulin</article-title><source>Mol Immunol</source><year>2010</year><volume>47</volume><fpage>1516</fpage><lpage>1521</lpage><pub-id pub-id-type="doi">10.1016/j.molimm.2010.01.019</pub-id><?supplied-pmid 20153898?><pub-id pub-id-type="pmid">20153898</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Obeid</surname><given-names>M</given-names></name><name><surname>Tesnierel</surname><given-names>A</given-names></name><name><surname>Ghiringhelli</surname><given-names>F</given-names></name><name><surname>Fimia</surname><given-names>GM</given-names></name><name><surname>Apetoh</surname><given-names>L</given-names></name><name><surname>Perfettini</surname><given-names>JL</given-names></name><etal/></person-group><article-title>Calreticulin exposure dictates the immunogenicity of cancer cell death</article-title><source>Nat Med</source><year>2007</year><volume>13</volume><fpage>54</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1038/nm1523</pub-id><?supplied-pmid 17187072?><pub-id pub-id-type="pmid">17187072</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colombo</surname><given-names>A</given-names></name><name><surname>Molina</surname><given-names>MC</given-names></name><name><surname>Ferreira</surname><given-names>L</given-names></name><name><surname>Lorca</surname><given-names>M</given-names></name><name><surname>Aguill&#x000f3;n</surname><given-names>JC</given-names></name><etal/></person-group><article-title>Development of an immunoenzymatic assay for the detection of human antibodies against <italic>Trypanosoma cruzi</italic> calreticulin, an immunodominant antigen</article-title><source>Acta Trop</source><year>2000</year><volume>75</volume><fpage>291</fpage><lpage>300</lpage><pub-id pub-id-type="doi">10.1016/S0001-706X(00)00062-0</pub-id><?supplied-pmid 10838212?><pub-id pub-id-type="pmid">10838212</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ribeiro</surname><given-names>C</given-names></name><name><surname>L&#x000f3;pez</surname><given-names>N</given-names></name><name><surname>Ram&#x000ed;rez</surname><given-names>G</given-names></name><name><surname>Valck</surname><given-names>C</given-names></name><name><surname>Molina</surname><given-names>M</given-names></name><name><surname>Aguilar</surname><given-names>L</given-names></name><etal/></person-group><article-title><italic>Trypanosoma cruzi</italic> calreticulin: a possible role in Chagas&#x02019; disease autoimmunity</article-title><source>Mol Immunol</source><year>2009</year><volume>46</volume><fpage>1092</fpage><lpage>1099</lpage><pub-id pub-id-type="doi">10.1016/j.molimm.2008.10.034</pub-id><?supplied-pmid 19108895?><pub-id pub-id-type="pmid">19108895</pub-id></element-citation></ref></ref-list></back></article>